|
|
D J Rader, W Cain, K Ikewaki, G Talley, L A Zech, D Usher, H B Brewer
J Clin Invest. 1994;
93(6):2758
doi:10.1172/JCI117292
Abstract |
Full text
| PDF

L
ipoprotein(a) (Lp[a]) is an atherogenic lipoprotein which is similar in structure to low density lipoproteins (LDL) but contains an additional protein called apolipoprotein(a) (apo[a]). Apo(a) is highly polymorphic in size, and there is a strong inverse association between the size of the apo(a) isoform and the plasma concentration of Lp(a). We directly compared the in vivo catabolism of Lp(a) particles containing different size apo(a) isoforms to establish whether there is an effect of apo(a) isoform size on the catabolic rate of Lp(a). In the first series of studies, four normal subjects were injected with radio-labeled S1-Lp(a) and S2-Lp(a) and another four subjects were injected with radiolabeled S2-Lp(a) and S4-Lp(a). No significant differences in fractional catabolic rate were found between Lp(a) particles containing different apo(a) isoforms. To confirm that apo(a) isoform size does not influence the rate of Lp(a) catabolism, three subjects heterozygous for apo(a) were selected for preparative isolation of both Lp(a) particles. The first was a B/S3-apo(a) subject, the second a S4/S6-apo(a) subject, and the third an F/S3-apo(a) subject. From each subject, both Lp(a) particles were preparatively isolated, radiolabeled, and injected into donor subjects and normal volunteers. In all cases, the catabolic rates of the two forms of Lp(a) were not significantly different. In contrast, the allele-specific apo(a) production rates were more than twice as great for the smaller apo(a) isoforms than for the larger apo(a) isoforms. In a total of 17 studies directly comparing Lp(a) particles of different apo(a) isoform size, the mean fractional catabolic rate of the Lp(a) with smaller size apo(a) was 0.329 +/- 0.090 day-1 and of the Lp(a) with the larger size apo(a) 0.306 +/- 0.079 day-1, not significantly different. In summary, the inverse association of plasma Lp(a) concentrations with apo(a) isoform size is not due to differences in the catabolic rates of Lp(a) but rather to differences in Lp(a) production rates.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(33)
| Title and authors |
Publication |
Year |
Farnesoid X receptor represses hepatic human APOA gene expression
Indumathi Chennamsetty, Thierry Claudel, Karam M. Kostner, Anna Baghdasaryan, Dagmar Kratky, Sanja Levak-Frank, Sasa Frank, Frank J. Gonzalez, Michael Trauner, Gert M. Kostner
|
J. Clin. Invest.
|
2011 |
Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists
Michael H. Davidson, Christie M. Ballantyne, Terry A. Jacobson, Vera A. Bittner, Lynne T. Braun, Alan S. Brown, W.Virgil Brown, William C. Cromwell, Ronald B. Goldberg, James M. McKenney, Alan T. Remaley, Allan D. Sniderman, Peter P. Toth, Sotirios Tsimikas, Paul E. Ziajka, Kevin C. Maki, Mary R. Dicklin
|
Journal of Clinical Lipidology
|
2011 |
Lipoprotein(a) as a cardiovascular risk factor: current status
B. G. Nordestgaard, M. J. Chapman, K. Ray, J. Boren, F. Andreotti, G. F. Watts, H. Ginsberg, P. Amarenco, A. Catapano, O. S. Descamps, E. Fisher, P. T. Kovanen, J. A. Kuivenhoven, P. Lesnik, L. Masana, Z. Reiner, M.-R. Taskinen, L. Tokgozoglu, A. Tybjaerg-Hansen
|
European Heart Journal
|
2010 |
Lipoprotein(a): From Molecules to Therapeutics
Valmore Bermúdez, Nailet Arráiz, Daniel Aparicio, Edward Rojas, Daniela Gotera, Xavier Guerra, Roger Canelón, Judith Faría, Luis Sorell, Anilsa Amell, Nadia Reyna, Mayela Cabrera, Edgardo Mengual, Raquel Cano, Clímaco Cano, Manuel Velasco
|
American Journal of Therapeutics
|
2010 |
Biogenesis of Lp(a) in transgenic mouse hepatocytes
Ann L. White
|
Clinical Genetics
|
2008 |
Lipoprotein(a), Hormone Replacement Therapy, and Risk of Future Cardiovascular Events
Jacqueline Suk Danik, Nader Rifai, Julie E. Buring, Paul M. Ridker
|
Journal of the American College of Cardiology
|
2008 |
In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients
M E Frischmann, F Kronenberg, E Trenkwalder, J R Schaefer, H Schweer, B Dieplinger, P Koenig, K Ikewaki, H Dieplinger
|
Kidney Int
|
2007 |
Lipoprotein(a) and Thrombocytes: Potential Mechanisms Underlying Cardiovascular Risk
William Discepolo, Ted Wun, Lars Berglund
|
Pathophysiol Haemos Thromb
|
2006 |
New risk factors for atherosclerosis in hypertension: focus on the prothrombotic state and lipoprotein(a)
Cristiana Catena, Marileda Novello, Roberta Lapenna, Sara Baroselli, Gianluca Colussi, Elisa Nadalini, Grazia Favret, Alessandro Cavarape, Giorgio Soardo, Leonardo A Sechi
|
Journal of Hypertension
|
2005 |
The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings
Jennifer L. Jenner, Leo J. Seman, John S. Millar, Stefania Lamon-Fava, Francine K. Welty, Gregory G. Dolnikowski, Santica M. Marcovina, Alice H. Lichtenstein, P. Hugh R. Barrett, Carl deLuca, Ernst J. Schaefer
|
Metabolism
|
2005 |
|